

Chemsex use and incidence of sexually transmitted infections in the l'Actuel pre-exposure prophylaxis (PrEP) cohort in Montréal (2013-2020)

The 30th Annual Canadian Conference on HIV/AIDS Research

Jorge Luis Flores Anato¹, Dimitra Panagiotoglou¹, Zoë R Greenwald^{2,3},
Maxime Blanchette⁴, Claire Trottier³, Maliheh Vaziri³, Louise Charest³,
Jason Szabo³, Réjean Thomas³, Mathieu Maheu-Giroux¹


1 – McGill University, Department of Epidemiology, Biostatistics and Occupational Health

2 – University of Toronto, Dalla Lana School of Public Health

3 – Clinique Médicale l'Actuel

4 – Université du Québec en Abitibi-Témiscamingue

Introduction



Background

- gbMSM experience syndemics of HIV, STIs, mental health and substance use, meaning components are mutually reinforcing and perpetuate health disparities
- Within the past decade, **chemsex** and **PrEP** have changed the syndemic
 - **Chemsex** is defined as intentional use of illicit substances during sex, associated with increases in STI and HIV transmission, and with poorer mental health
 - **PrEP** is a highly effective HIV-prevention tool, available in Quebec since 2013, possibly linked to higher STI transmission due to risk compensation
- Past evidence on chemsex-STI association mostly cross-sectional or qualitative

Research question

Is chemsex associated with higher STI incidence among PrEP users?

gbMSM: gay, bisexual and other men who have sex with men;
PrEP: pre-exposure prophylaxis; STIs: sexually transmitted infections.

Methods

Study population

- *L'Actuel PrEP cohort*, a large prospective cohort with quarterly follow-up and STI screening (study period: 2013–2020)
- Selection criteria
 - Adult gbMSM and transgender women
 - HIV-negative at baseline
 - Initiated PrEP (≥ 1 follow-up visit)

Exposure definitions

- **Chemsex** defined as reporting, at baseline, sex in the past year while under the influence of
 - Ecstasy, GHB, cocaine, crystal meth, ketamine or crack
- **Polysubstance use** defined as reporting ≥ 2 substances

Survival analysis

- **Outcome:** time to first STI diagnosis
 - Laboratory-confirmed diagnosis (NAAT)
 - **STI:** either gonorrhea or chlamydia
- **Time zero:** first PrEP consultation
- **Censoring:** reaching 2 years of follow-up, stopping follow-up, or discontinuing PrEP
- Kaplan-Meier curves and Cox proportional hazards regression adjusted for
 - Age (categorized),
 - Education (post-secondary vs not),
 - Income (categorized),
 - PrEP regimen (daily vs intermittent),
 - Year of entry into cohort (categorized)
- **Effect modification** analysis by including product terms for chemsex with age and income

gbMSM: gay, bisexual and other men who have sex with men;
NAAT: nucleic acid amplification test PrEP: pre-exposure prophylaxis;
STIs: sexually transmitted infections.

Results

- Adjusted HR
1.35 (95% CI 1.13–1.62)

*Dichotomous chemsex variable:
chemsex at baseline vs not*

Adjusted regression

- Chemsex HR
1.14 (95% CI 0.89–1.46)
- Polysubstance HR
1.58 (95% CI 1.26–1.97)

*Trichotomous chemsex variable:
no chemsex, 1 substance reported,
polysubstance use*




Fig 1. Chemsex at baseline is associated with higher STI incidence




Fig 2. Polysubstance use has a stronger association with STI incidence




Fig 3. There is effect modification of the chemsex-STI association by age and income

*Dichotomous chemsex variable:
chemsex at baseline vs not*

All analyses are adjusted for age (categorical), education, income, PrEP regimen and year of entry into the cohort (categorical)

HR: hazard ratio; STIs: sexually transmitted infections.

Conclusions and acknowledgements



Department of Epidemiology,
Biostatistics and Occupational Health



Conclusions

- Chemsex at baseline is associated with higher hazard of STI diagnosis among gbMSM using PrEP
- The magnitude of the association is stronger among gbMSM who are ≤ 35 years old and those reporting yearly income of $\leq \$35k$
- High STI incidence highlights (1) need for integrated services for gbMSM who practice chemsex and (2) that PrEP is an important harm-reduction intervention (no incident HIV infections)

Strengths

- Large sample size and 7-year timespan
- Lab-confirmed diagnosis and regular screening

Limitations

- Exposure only measured at baseline
- Did not account for recurrent infections
- Not enough transgender women for stratified results

Acknowledgements

- My supervisors Mathieu Maheu-Giroux and Dimitra Panagiotoglou
- Staff at Clinique l'Actuel and all participating patients
- All research group members for their advice and feedback
- This masters research project was supported by CIHR